|
注册号: Registration number: |
ChiCTR2300078062 |
|
最近更新日期: Date of Last Refreshed on: |
2024-07-15 23:32:52 |
|
注册时间: Date of Registration: |
2023-11-28 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
TMAO在中国健康人群中的基线水平及其影响因素研究 |
|
Public title: |
Baseline level and influencing factors of TMAO in Chinese healthy population |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
TMAO在中国健康人群中的基线水平及其影响因素研究 |
|
Scientific title: |
Baseline level and influencing factors of TMAO in Chinese healthy population |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
方青 |
研究负责人: |
欧阳冬生 |
|
Applicant: |
Qing Fang |
Study leader: |
Dongsheng Ouyang |
|
申请注册联系人电话: Applicant telephone: |
+86 153 0749 8190 |
研究负责人电话:
Study leader's |
+86 133 0731 3736 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
qing.fang@duxact.com |
研究负责人电子邮件: Study leader's E-mail: |
dongsheng.ouyang@duxact.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南省长沙市高新区麓天路28号麓谷科技产业园C10栋 |
研究负责人通讯地址: |
湖南省长沙市湘雅路87号 |
|
Applicant address: |
Building C10, Lugu Science and Technology Industrial Park, 28 Lutian Road, High-tech Zone, Changsha, Hunan |
Study leader's address: |
87 Xiangya Road, Changsha, Hunan |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
长沙都正生物科技股份有限公司 |
||
|
Applicant's institution: |
Changsha Duxact Biotech Co.,Ltd. |
||
|
研究负责人所在单位: |
中南大学湘雅医院临床药理研究所 |
||
|
Affiliation of the Leader: |
Institute of Clinical Pharmacology, Central South University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦申科第(快 202205304)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中南大学湘雅医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Xiangya Hospital Central South University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-06-06 00:00:00 | ||
|
伦理委员会联系人: |
刘星 |
||
|
Contact Name of the ethic committee: |
Xing Liu |
||
|
伦理委员会联系地址: |
湖南省长沙市湘雅路87号 |
||
|
Contact Address of the ethic committee: |
87 Xiangya Road, Changsha, Hunan |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 731 8432 7919 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中南大学湘雅医院临床药理研究所 |
||||||||||||||||||||||
|
Primary sponsor: |
Institute of Clinical Pharmacology, Central South University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖南省长沙市湘雅路87号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
87 Xiangya Road, Changsha, Hunan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-funded |
||||||||||||||||||||||
|
研究疾病: |
健康人群,不涉及疾病 |
||||||||||||||||||||||
|
Target disease: |
None |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
基础科学研究 |
||||||||||||||||||||||
|
Study type: |
Basic Science |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
建立中国健康人群TMAO的数据库及检测基线值,探索年龄、性别、BMI、民族,以及各体检结果等因素对血浆TMAO水平的影响;明确抗凝剂、离心前放置环境的温度及时间等样本处理前影响因素对人血液样本中TMAO稳定性的影响,为TMAO开发成为中国人群疾病风险预警因子及治疗靶标提供理论依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To establish a database of TMAO in healthy Chinese population and detect baseline values, explore the influence of factors such as age, gender, BMI, ethnicity, and physical examination results on plasma TMAO levels; clarify anticoagulant, temperature and time of the environment before centrifugation and other sample processing. The influence of the former influencing factors on the stability of TMAO in human blood samples provides a theoretical basis for the development of TMAO as a disease risk early warning factor and a therapeutic target in the Chinese population. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
无 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.年龄<18岁或>75岁; 2.确诊患有严重心脑血管疾病、糖尿病、慢性肾病、恶性肿瘤等重大疾病; 3.孕妇、哺乳期妇女、服用避孕药者; 4.不愿意参加本研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Aged < 18 years old or > 75 years old; 2. Diagnosed with severe cardiovascular and cerebrovascular diseases, diabetes, chronic kidney disease, malignant tumors and other major diseases; 3. Pregnant women, lactating women, those taking contraceptives; 4. Unwilling to participate in this researcher. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-07-10 00:00:00至 To 2024-06-06 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-07-10 00:00:00 至 To 2024-06-06 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NA |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
临床试验公共管理平台 IPD(http://www.medresman.org.cn)。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan IPD (http://www.medresman.org.cn). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |